{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide-ppis","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide-ppis/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-ppis/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide-ppis","title":"Retatrutide and PPIs: Evidence on Weight Loss Pathways and Acid Suppression Effects","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:20.482Z","body_excerpt":"## What's breaking down if you have PPIs (omeprazole, etc.)\n\nLong-term use of proton pump inhibitors like omeprazole suppresses stomach acid production. This can reduce symptoms of acid reflux or ulcers in the short term. Over time, reduced acid may affect nutrient absorption, including calcium, magnesium, and vitamin B12. Observational data link extended PPI use to higher rates of certain deficiencies and possible bone density changes.\n\nIf excess body weight is also present, compressive forces on the spine, hips, and knees increase. Each extra pound of body weight adds roughly four pounds of force on the lower back during standing or walking. The combination of acid suppression effects and mechanical loading can compound issues in musculoskeletal tissues.\n\nRetatrutide targets metabolic pathways tied to body weight. It does not directly address acid production or mucosal repair.\n\n## Why Retatrutide might help you\n\n1. You are reading about **PPIs (omeprazole, etc.)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf body weight contributes to ongoing mechanical stress, reduced load through studied weight-loss pathways may allow tissues more opportunity for natural repair processes. This differs from direct symptom suppression.\n\n## Why PPIs (omeprazole, etc.) matters for you\n\n**Drug:** PPIs (omeprazole, etc.)\n\n**What it does:** Acid suppression; long-term mucosal and nutrient consequences.\n\n**Therefore for you:** This drug suppresses a signal (acid production). It reduces immediate reflux symptoms but can trade off repair support by altering nutrient absorption over time. It does not reduce mechanical load from body weight.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide addresses the metabolic and load layer through weight reduction. PPIs address symptom suppression via acid control. The two operate on separate pathways: one influences overall body mass and associated forces, the other modulates gastric acidity. Any combined effect on repair would depend on individual factors such as baseline weight and duration of PPI use.\n\n## What the evidence actually shows\n\nHuman trials of retatrutide demonstrate substantial weight reduction. In a phase 2 study of 338 adults with obesity, the 12 mg dose produced a least-squares mean weight change of -24.2% at 48 weeks versus -2.1% on placebo. More than 80% of participants on the highest dose achieved at least 15% weight loss. Phase 3 data from TRIUMPH-1 showed average losses up to 28.3% at 80 weeks on 12 mg, with further extension to 30.3% at 104 weeks in a subset. These are human randomized controlled trial results.\n\nNo human trials directly examine retatrutide in people taking PPIs. No published data link the two compounds.\n\nFor PPIs, human observational studies associate long-term use with nutrient deficiencies. One analysis found 12-18% reductions in serum B12 after 12 months. Other reports note lower calcium and magnesium levels and possible associations with reduced bone density. These are not randomized trials proving causation.\n\nNo preclinical (rat or other animal) data appear in the reviewed sources for this specific cross.\n\n## What scientists say\n\nPublished reviews describe retatrutide as producing dose-dependent weight loss with gastrointestinal side effects that are mostly mild to moderate. Scientists note the triple-agonist mechanism (GLP-1, GIP, glucagon) d","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c2","text":"Phase 3 TRIUMPH-1 data showed up to 28.3% average weight loss at 80 weeks on 12 mg retatrutide.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Confirms larger-scale human weight loss results.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Long-term PPI use is associated with 12-18% reductions in serum B12 in human observational data.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Documents nutrient consequence layer of PPIs.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"No human trials examine retatrutide in participants taking PPIs.","tier":"mechanistic","weight":0.3,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct cross evidence.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c1","text":"In a phase 2 human trial, retatrutide 12 mg produced -24.2% mean weight change at 48 weeks versus -2.1% placebo.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes magnitude of weight loss in humans, relevant to metabolic load layer.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 RCT results showing dose-dependent weight loss with retatrutide.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"023b023cb614db520180ebf4e78c5d283079d9c065a61399f952d94c3542a028"},{"id":"s2","type":"news","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial","quote":"participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively.","summary":"Phase 3 topline weight loss percentages.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"987d8f52c309e5c1087a946af2a778da4f24fd8759007691fffbbb5efac68583"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12456669/","title":"A Systematic Review of Long-Term Use of Proton Pump Inhibitors","quote":"Results showed a 12-18% reduction in serum vitamin B12 over 12 months of PPI use.","summary":"Observational findings on B12 changes with PPIs.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"ecb68ab41cbbe62aa48ca4604d3609bc8875b7af7440800f5155fcf0027fda26"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 RCT results showing dose-dependent weight loss with retatrutide.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"023b023cb614db520180ebf4e78c5d283079d9c065a61399f952d94c3542a028"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12456669/","title":"A Systematic Review of Long-Term Use of Proton Pump Inhibitors","quote":"Results showed a 12-18% reduction in serum vitamin B12 over 12 months of PPI use.","summary":"Observational findings on B12 changes with PPIs.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"ecb68ab41cbbe62aa48ca4604d3609bc8875b7af7440800f5155fcf0027fda26"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"retatrutide-ppis","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":3,"anecdotal":0,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}